Nexplanon: The new implant for long-term contraception. A comprehensive descriptive review

Gynecological Endocrinology

Volumn 28, Issue 9, 2012, Pages 710-721

  Palomba, Stefano ^a   Falbo, Angela ^a   Di Cello, Annalisa ^a   Materazzo, Caterina ^a   Zullo, Fulvio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Contraceptive efficacy; Etonogestrel; Implanon; Long acting contraceptive; Nexplanon

Indexed keywords

ETONOGESTREL; MEFENAMIC ACID; MIFEPRISTONE; TRANEXAMIC ACID;

ACNE; ARTICLE; BLEEDING; CONTRACEPTION; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; EMOTIONAL DISORDER; ENDOMETRIOSIS; HIRSUTISM; HUMAN; LONG TERM CARE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT GAIN;

CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; FEMALE; HUMANS;

EID: 84865320892     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2011.652247     Document Type: Article

References (78)

1. Graesslin O, Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care 2008;13 Suppl 1:4-12. (Pubitemid 351364455)
2. Harrison-Woolrych M, Hill R. Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia. Contraception 2005;71:306-308. (Pubitemid 40410081)
3. Jaffer K, Whalen S. Self removal of Implanon: a case report. J Fam Plann Reprod Health Care 2005;31:248. (Pubitemid 41044440)
4. Gwinnell E. Expulsion of Implanon. J Fam Plann Reprod Health Care 2007;33:211.
5. Mansour D. Nexplanon(®): what Implanon(®) did next. J Fam Plann Reprod Health Care 2010;36:187-189.
6. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006;12:169-178. (Pubitemid 43231449)
7. Sitruk-Ware R, Nath A. Metabolic effects of contraceptive steroids. Rev Endocr Metab Disord 2011;12:63-75.
8. Mäkäräinen L, van Beek A, Tuomivaara L, Asplund B, Coelingh Bennink H. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril 1998;69:714-721. (Pubitemid 28188469)
9. Wenzl R, van Beek A, Schnabel P, Huber J. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon. Contraception 1998;58:283-288. (Pubitemid 29036549)
10. Bennink HJ. The pharmacokinetics and pharmacodynamics of Implanon, a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000;5 Suppl 2:12-20. (Pubitemid 32171233)
11. Díaz S, Pavez M, Moo-Young AJ, Bardin CW, Croxatto HB. Clinical trial with 3-keto-desogestrel subdermal implants. Contraception 1991;44: 393-408.
12. Croxatto HB. Mechanisms that explain the contraceptive action of progestin implants for women. Contraception 2002;65:21-27. (Pubitemid 34175235)
13. Davies GC, Feng LX, Newton JR, Van Beek A, Coelingh-Bennink HJ. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel. Contraception 1993;47:251-261. (Pubitemid 23107285)
14. Van den Bosch T, Donders GG, Riphagen I, Debois P, Ameye L, De Brabanter J, Van Huffel S, et al. Ultrasonographic features of the endometrium and the ovaries in women on etonogestrel implant. Ultrasound Obstet Gynecol 2002;20:377-380. (Pubitemid 35253736)
15. Varma R, Mascarenhas L. Endometrial effects of etonogestrel (Implanon) contraceptive implant. Curr Opin Obstet Gynecol 2001;13:335-341. (Pubitemid 32673536)
16. Lortlar N, Kilic S, Peker T, Zulfikaroglu E, Omeroglu S, Erbas D, Celik HH, et al. The long-term effects of progesterone-only contraceptives on endometrium and ovary in rats. Arch Gynecol Obstet 2010;281:1051-1059.
17. Shulman LP, Gabriel H. Management and localization strategies for the nonpalpable Implanon rod. Contraception 2006;73:325-330. (Pubitemid 43375088)
18. Mansour D, Inki P, Gemzell-Danielsson K. Efficacy of contraceptive methods: A review of the literature. Eur J Contracept Reprod Health Care 2010;15:4-16.
19. Gillies R, Scougall P, Nicklin S. Etonogestrel implants - case studies of median nerve injury following removal. Aust Fam Physician 2011;40:799-800
20. Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril 2009;91:1646-1653.
21. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice; Long-Acting Reversible Contraception Working Group. ACOG Committee Opinion no. 450: Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol 2009;114:1434-1438.
22. Food and Drug Administration. Second report on intrauterine contraceptive devices. Washington (DC): Food and Drug Administraction;1978.
23. Funk S, Miller MM, Mishell DR Jr, Archer DF, Poindexter A, Schmidt J, Zampaglione E; Implanon US Study Group. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005;71:319-326. (Pubitemid 40602307)
24. Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 2008;13 Suppl 1:13-28. (Pubitemid 351364453)
25. Casey PM, Long ME, Marnach ML, Bury JE. Bleeding related to etonogestrel subdermal implant in a US population. Contraception 2011;83:426-430.
26. Walch K, Unfried G, Huber J, Kurz C, van Trotsenburg M, Pernicka E, Wenzl R. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis-a pilot study. Contraception 2009;79:29-34.
27. Shokeir T, Amr M, Abdelshaheed M. The efficacy of Implanon for the treatment of chronic pelvic pain associated with pelvic congestion: 1-year randomized controlled pilot study. Arch Gynecol Obstet 2009;280:437-443.
28. Power J, French R, Cowan F. Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods of preventing pregnancy. Cochrane Database Syst Rev 2007:CD001326.
29. Belsey EM, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 1986;34: 253-260. (Pubitemid 17177017)
30. Belsey EM, Farley TM. The analysis of menstrual bleeding patterns: a review. Contraception 1988;38:129-156.
31. Blumenthal PD, Gemzell-Danielsson K, Marintcheva-Petrova M. Tolerability and clinical safety of Implanon. Eur J Contracept Reprod Health Care 2008;13 Suppl 1:29-36.
32. Abdel-Aleem H, d'Arcangues C, Vogelsong KM, Gülmezoglu AM. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev 2007: CD003449.
33. Alvarez-Sanchez F, Brache V, Thevenin F, Cochon L, Faundes A. Hormonal treatment for bleeding irregularities in Norplant implant users. Am J Obstet Gynecol 1996;174:919-922. (Pubitemid 26111671)
34. Witjaksono J, Lau TM, Affandi B, Rogers PA. Oestrogen treatment for increased bleeding in Norplant users: preliminary results. Hum Reprod 1996;11 Suppl 2:109-114.
35. Díaz S, Croxatto HB, Pavez M, Belhadj H, Stern J, Sivin I. Clinical assessment of treatments for prolonged bleeding in users of Norplant implants. Contraception 1990;42:97-109. (Pubitemid 20208814)
36. Cheng L, Zhu H, Wang A, Ren F, Chen J, Glasier A. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum Reprod 2000;15:1969-1972.
37. Weisberg E, Hickey M, Palmer D, O'Connor V, Salamonsen LA, Findlay JK, Fraser IS. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod 2006;21:295-302. (Pubitemid 41794324)
38. Abdel-Aleem H, Shaaban OM, Amin AF, Abdel-Aleem AM. Tamoxifen treatment of bleeding irregularities associated with Norplant use. Contraception 2005;72:432-437. (Pubitemid 41679344)
39. Subakir SB, Setiadi E, Affandi B, Pringgoutomo S, Freisleben HJ. Benefits of vitamin E supplementation to Norplant users-in vitro and in vivo studies. Toxicology 2000;148:173-178. (Pubitemid 30621357)
40. d'Arcangues C, Piaggio G, Brache V, Aissa RB, Hazelden C, Massai R, Pinol A, et al.; Study Group on Progestogen-induced Vaginal Bleeding Disturbances. Effectiveness and acceptability of vitamin E and low-dose aspirin, alone or in combination, on Norplant-induced prolonged bleeding. Contraception 2004;70:451-462. (Pubitemid 39488201)
41. Kaewrudee S, Taneepanichskul S, Jaisamraun U, Reinprayoon D. The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use. Contraception 1999;60:25-30. (Pubitemid 29505352)
42. Lukes AS, Moore KA, Muse KN, Gersten JK, Hecht BR, Edlund M, Richter HE, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010;116:865-875.
43. Weisberg E, Hickey M, Palmer D, O'Connor V, Salamonsen LA, Findlay JK, Fraser IS. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod 2009;24:1852-1861.
44. Weisberg E, Croxatto HB, Findlay JK, Burger H, Fraser IS. A randomized study of the effect of mifepristone alone or in conjunction with ethinyl estradiol on ovarian function in women using the etonogestrelreleasing subdermal implant, Implanon®. Contraception 2011;84(6): 600-8.
45. Bitzer J, Tschudin S, Alder J; Swiss Implanon Study Group. Acceptability and side-effects of Implanon in Switzerland: a retrospective study by the Implanon Swiss Study Group. Eur J Contracept Reprod Health Care 2004;9:278-284. (Pubitemid 40093198)
46. Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A long-term study of the efficacy and acceptability of a single-rod hormonal contraceptive implant (Implanon) in healthy women in China. Eur J Contracept Reprod Health Care 1999;4:85-93. (Pubitemid 29318067)
47. Dorflinger LJ. Metabolic effects of implantable steroid contraceptives for women. Contraception 2002;65:47-62. (Pubitemid 34175238)
48. Merki-Feld GS, Imthurn B, Seifert B. Effects of the progestagen-only contraceptive implant Implanon on cardiovascular risk factors. Clin Endocrinol (Oxf) 2008;68:355-360. (Pubitemid 351257852)
49. Merki-Feld GS, Rosselli M, Imthurn B, Spanaus K. No effect of Implanon® on inflammatory cardiovascular parameters. Gynecol Endocrinol 2011;27:951-955.
50. Guazzelli CA, de Queiroz FT, Barbieri M, Barreiros FA, Torloni MR, Araujo FF. Metabolic effects of contraceptive implants in adolescents. Contraception 2011;84:409-412.
51. Biswas A, Viegas OA, Coeling Bennink HJ, Korver T, Ratnam SS. Implanon contraceptive implants: effects on carbohydrate metabolism. Contraception 2001;63:137-141. (Pubitemid 32451805)
52. Oderich CL, Wender MC, Lubianca JN, Santos LM, de Mello GC. Impact of etonogestrel-releasing implant and copper intrauterine device on carbohydrate metabolism: a comparative study. Contraception. 2011 Sep 17.
53. Vieira CS, Ferriani RA, Garcia AA, Pintão MC, Azevedo GD, Gomes MK, Silva-de-Sá MF. Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. Hum Reprod 2007;22:2196-2201. (Pubitemid 47241866)
54. Beerthuizen R, van Beek A, Massai R, Mäkäräinen L, Hout J, Bennink HC. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod 2000;15:118-122. (Pubitemid 30035110)
55. Bahamondes L, Monteiro-Dantas C, Espejo-Arce X, Dos Santos Fernandes AM, Lui-Filho JF, Perrotti M, Petta CA. A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrelreleasing contraceptive implants. Hum Reprod 2006;21:466-470. (Pubitemid 43159924)
56. Morrison CS, Turner AN, Jones LB. Highly effective contraception and acquisition of HIV and other sexually transmitted infections. Best Pract Res Clin Obstet Gynaecol 2009;23:263-284.
57. Stringer EM, Giganti M, Carter RJ, El-Sadr W, Abrams EJ, Stringer JS; MTCT-Plus Initiative. Hormonal contraception and HIV disease progression: a multicountry cohort analysis of the MTCT-Plus Initiative. AIDS 2009;23 Suppl 1:S69-S77.
58. Bazin B, Thevenot R, Bursaux C, Paris J. Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary-ovarian function in women. Br J Obstet Gynaecol 1987;94:1199-1204. (Pubitemid 18058561)
59. National Institute for Health and Clinical Excellence. Long-acting reversible contraception: NICE guideline2005.Avilable at: www.nice.org.uk/CG30.
60. Church E, Sengupta S, Chia KV. The contraceptive implant for long acting reversible contraception in patients undergoing first trimester medical termination of pregnancy. Sex Reprod Healthc 2010;1:105-109.
61. MSD. Implanon data on file, July 2010.
62. IMPLANON [package insert]. Schering-Plough Corporation, 2006.
63. Kittur ND, Secura GM, Peipert JF, Madden T, Finer LB, Allsworth JE. Comparison of contraceptive use between the Contraceptive CHOICE Project and state and national data. Contraception 2011;83:479-485.
64. Lipetz C, Phillips CJ, Fleming CF. The cost-effectiveness of a long-acting reversible contraceptive (Implanon) relative to oral contraception in a community setting. Contraception 2009;79:304-309.
65. Tocce K, Sheeder J, Python J, Teal SB. Long acting reversible contraception in postpartum adolescents: early initiation of etonogestrel implant is superior to IUDs in the outpatient setting. J Pediatr Adolesc Gynecol 2012;25:59-63.
66. Lewis LN, Doherty DA, Hickey M, Skinner SR. Implanon as a contraceptive choice for teenage mothers: a comparison of contraceptive choices, acceptability and repeat pregnancy. Contraception 2010;81:421-426.
67. Available at: www.Din-Linkdatabase.org (MAT Feb 2007).
68. Booranabunyat S, Taneepanichskul S. Implanon use in Thai women above the age of 35 years. Contraception 2004;69:489-491. (Pubitemid 38638750)
69. Croxatto HB, Urbancsek J, Massai R, Coelingh Bennink H, van Beek A. A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. Hum Reprod 1999;14: 976-981. (Pubitemid 29176477)
70. Flores JB, Balderas ML, Bonilla MC, Vázquez-Estrada L. Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant. Int J Gynaecol Obstet 2005;90:228-233. (Pubitemid 41138922)
71. Lopez LM, Grimes DA, Chen-Mok M, Westhoff C, Edelman A, Helmerhorst FM. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev 2010:CD008452.
72. Medical eligibility criteria for contraceptive use. 4rd ed. WHO Library Cataloguing-in-Publication Data, World Health Organization; 2009.
73. Brito MB, Ferriani RA, Quintana SM, Yazlle ME, Silva de Sá MF, Vieira CS. Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. Contraception 2009;80:519-526.
74. Taneepanichskul S, Reinprayoon D, Thaithumyanon P, Praisuwanna P, Tosukhowong P, Dieben T. Effects of the etonogestrel-releasing implant Implanon and a nonmedicated intrauterine device on the growth of breast-fed infants. Contraception 2006;73:368-371. (Pubitemid 43375097)
75. Gurtcheff SE, Turok DK, Stoddard G, Murphy PA, Gibson M, Jones KP. Lactogenesis after early postpartum use of the contraceptive implant: a randomized controlled trial. Obstet Gynecol 2011;117: 1114-1121.
76. Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet 2008;371:1200-1210. (Pubitemid 351458526)
77. Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998;30:89-92.
78. Leticee N, Viard JP, Yamgnane A, Karmochkine M, Benachi A. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. Contraception 2011 Oct 27.